Serum hepcidin and GlycA diagnostic testing reimbursement
Defines UnitedHealthcare Medicare Advantage reimbursement stance for serum hepcidin testing (including immunoassays) and GlycA testing when used to monitor transferrin or other glycosylated proteins for iron homeostasis and metabolism; applies to Medicare Advantage providers submitting CMS 1500 or UB04 claims.
No material clinical or coverage changes in this revision.
Coverage Determinations
Non‑reimbursed diagnostic tests
UnitedHealthcare Medicare Advantage will not reimburse the following tests when used to monitor transferrin or other glycosylated proteins for iron homeostasis and metabolism:
ALL of the following
Tests not reimbursed
- Serum hepcidin testing, including immunoassays
- GlycA testing
Procedure Codes
| 0024U | Serum hepcidin testing (listed in document) |
| 0251U | GlycA testing (listed in document) |
Provider Billing & Authorization Guidance
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.